secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001077183-23-000099
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q2 revenue up 18% to $147M; net loss narrows 31% to $24M
--------------------------------------------------------------------

- Revenue of $147M (+18% YoY); Clinical Services $123M (+17%), Advanced Diagnostics $24M (+22%).
- Net loss decreased 31% to $24M; Adjusted EBITDA improved 87% to -$2M from -$16M.
- Adjusted Net Loss $7M vs $20M in prior year; cash and marketable securities $409M.
- FY 2023 guidance raised: revenue $565-575M, net loss $(107)-(100)M, Adjusted EBITDA $(13)-(10)M.
- Pharma Services segment rebranded as Advanced Diagnostics; restructuring charges included in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718323000099/0001077183-23-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718323000099/neo-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001077183-23-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer